Shopping Cart 0
Cart Subtotal
AED 0

PharmSource-Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7322

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14643

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 21965

Details

PharmSource-Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Summary

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, "PharmSource-Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a "boom or bust" proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Scope

Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Reasons to Buy

This report provides important insight that you won't find in any other source. This report is required reading for

CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking

Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence

Private equity: investment targeting, portfolio company performance benchmarking

READ MORE

Table Of Content

Scope

1 Table of Contents

Executive Summary 1

Context and Objectives 2

Clinical Trial Activity of Emerging Bio/Pharma Companies 4

Clinical Development Costs and Spending by Emerging Bio/Pharma Companies 7

External Financing for Emerging Bio/Pharma Companies 9

Outlook and What it Means 15

Appendix A 18

Appendix B 19


List Of Figure

1.2 List of Figures

Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016

Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre-and Post-IPO

Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre-and Post-SPO

Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases

Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016

Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016

Figure 7 Venture Capital Investment in Bio/Pharma Companies

Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015

Figure 9 NASDAQ Biotech Index January 13-December 2016

Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies

Figure 11 Revenue as a Funding Source for US Emerging BioPharma

Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves


List Of Table

1.1 List of Tables

Table 1 2016 Performance of Drug Development Service Providers

Table 2 Profile of Emerging Bio/Pharma IPOs 2014-2015

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

PharmSource-Follow the Money: The Outlook for Outsourced Spending on Early Development Services

Summary

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.

According to this latest report, "PharmSource-Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a "boom or bust" proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.

Scope

Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Reasons to Buy

This report provides important insight that you won't find in any other source. This report is required reading for

CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking

Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence

Private equity: investment targeting, portfolio company performance benchmarking

READ MORE

Scope

1 Table of Contents

Executive Summary 1

Context and Objectives 2

Clinical Trial Activity of Emerging Bio/Pharma Companies 4

Clinical Development Costs and Spending by Emerging Bio/Pharma Companies 7

External Financing for Emerging Bio/Pharma Companies 9

Outlook and What it Means 15

Appendix A 18

Appendix B 19


List Of Figure

1.2 List of Figures

Figure 1 Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016

Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre-and Post-IPO

Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre-and Post-SPO

Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases

Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016

Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016

Figure 7 Venture Capital Investment in Bio/Pharma Companies

Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015

Figure 9 NASDAQ Biotech Index January 13-December 2016

Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies

Figure 11 Revenue as a Funding Source for US Emerging BioPharma

Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves


List Of Table

1.1 List of Tables

Table 1 2016 Performance of Drug Development Service Providers

Table 2 Profile of Emerging Bio/Pharma IPOs 2014-2015

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS